JP2023516630A5 - - Google Patents
Info
- Publication number
- JP2023516630A5 JP2023516630A5 JP2022551825A JP2022551825A JP2023516630A5 JP 2023516630 A5 JP2023516630 A5 JP 2023516630A5 JP 2022551825 A JP2022551825 A JP 2022551825A JP 2022551825 A JP2022551825 A JP 2022551825A JP 2023516630 A5 JP2023516630 A5 JP 2023516630A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid pharmaceutical
- pharmaceutical composition
- composition according
- glycopyrrolate
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025203938A JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2002786.8 | 2020-02-27 | ||
| GBGB2002786.8A GB202002786D0 (en) | 2020-02-27 | 2020-02-27 | Liquid pharmaceutical composition |
| PCT/GB2021/050496 WO2021171034A1 (en) | 2020-02-27 | 2021-02-26 | Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203938A Division JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516630A JP2023516630A (ja) | 2023-04-20 |
| JP2023516630A5 true JP2023516630A5 (enExample) | 2024-02-29 |
| JP7781762B2 JP7781762B2 (ja) | 2025-12-08 |
Family
ID=70278709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551825A Active JP7781762B2 (ja) | 2020-02-27 | 2021-02-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
| JP2025203938A Pending JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203938A Pending JP2026035711A (ja) | 2020-02-27 | 2025-11-26 | エンシフェントリンおよびグリコピロレートを含む液体医薬組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20230112220A1 (enExample) |
| EP (2) | EP4110292B1 (enExample) |
| JP (2) | JP7781762B2 (enExample) |
| KR (1) | KR20220149669A (enExample) |
| CN (1) | CN115279343A (enExample) |
| AU (1) | AU2021227456A1 (enExample) |
| BR (1) | BR112022016015A2 (enExample) |
| CA (1) | CA3166952A1 (enExample) |
| DK (1) | DK4110292T3 (enExample) |
| ES (1) | ES2970571T3 (enExample) |
| FI (1) | FI4110292T3 (enExample) |
| GB (1) | GB202002786D0 (enExample) |
| HR (1) | HRP20240288T1 (enExample) |
| HU (1) | HUE065531T2 (enExample) |
| IL (1) | IL295442A (enExample) |
| LT (1) | LT4110292T (enExample) |
| MX (1) | MX2022010014A (enExample) |
| PH (1) | PH12022552278A1 (enExample) |
| PL (1) | PL4110292T3 (enExample) |
| PT (1) | PT4110292T (enExample) |
| RS (1) | RS65330B1 (enExample) |
| SI (1) | SI4110292T1 (enExample) |
| SM (1) | SMT202400076T1 (enExample) |
| WO (1) | WO2021171034A1 (enExample) |
| ZA (1) | ZA202208763B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3231444T3 (pl) | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| KR20250087621A (ko) * | 2022-10-28 | 2025-06-16 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| AU2024309346C1 (en) | 2023-06-26 | 2026-03-12 | Verona Pharma Plc | Particulate composition comprising ensifentrine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60005493T2 (de) | 1999-03-31 | 2004-07-01 | Vernalis Ltd., Wokingham | Pyrimido[6,1-a]isochinolinonderivate |
| CA2716936C (en) * | 2008-02-26 | 2018-06-05 | Elevation Pharmaceuticals, Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2968312B1 (en) * | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| MY196072A (en) * | 2014-09-15 | 2023-03-13 | Verona Pharma Plc | Liquid Inhalation Formulation Comprising RPL554 |
-
2020
- 2020-02-27 GB GBGB2002786.8A patent/GB202002786D0/en not_active Ceased
-
2021
- 2021-02-26 US US17/904,816 patent/US20230112220A1/en active Pending
- 2021-02-26 PL PL21709782.3T patent/PL4110292T3/pl unknown
- 2021-02-26 ES ES21709782T patent/ES2970571T3/es active Active
- 2021-02-26 AU AU2021227456A patent/AU2021227456A1/en active Pending
- 2021-02-26 LT LTEPPCT/GB2021/050496T patent/LT4110292T/lt unknown
- 2021-02-26 WO PCT/GB2021/050496 patent/WO2021171034A1/en not_active Ceased
- 2021-02-26 SM SM20240076T patent/SMT202400076T1/it unknown
- 2021-02-26 HR HRP20240288TT patent/HRP20240288T1/hr unknown
- 2021-02-26 EP EP21709782.3A patent/EP4110292B1/en active Active
- 2021-02-26 EP EP23213674.7A patent/EP4306129A3/en active Pending
- 2021-02-26 BR BR112022016015A patent/BR112022016015A2/pt unknown
- 2021-02-26 CN CN202180016396.7A patent/CN115279343A/zh active Pending
- 2021-02-26 RS RS20240350A patent/RS65330B1/sr unknown
- 2021-02-26 IL IL295442A patent/IL295442A/en unknown
- 2021-02-26 MX MX2022010014A patent/MX2022010014A/es unknown
- 2021-02-26 PT PT217097823T patent/PT4110292T/pt unknown
- 2021-02-26 KR KR1020227029927A patent/KR20220149669A/ko active Pending
- 2021-02-26 HU HUE21709782A patent/HUE065531T2/hu unknown
- 2021-02-26 SI SI202130101T patent/SI4110292T1/sl unknown
- 2021-02-26 FI FIEP21709782.3T patent/FI4110292T3/fi active
- 2021-02-26 DK DK21709782.3T patent/DK4110292T3/da active
- 2021-02-26 JP JP2022551825A patent/JP7781762B2/ja active Active
- 2021-02-26 PH PH1/2022/552278A patent/PH12022552278A1/en unknown
- 2021-02-26 CA CA3166952A patent/CA3166952A1/en active Pending
-
2022
- 2022-08-04 ZA ZA2022/08763A patent/ZA202208763B/en unknown
-
2025
- 2025-11-26 JP JP2025203938A patent/JP2026035711A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023516630A5 (enExample) | ||
| JP2017528479A5 (enExample) | ||
| HRP20240288T1 (hr) | Tekući farmaceutski sastav koji sadrži ensifentrin i glikopirolat | |
| HRP20211035T1 (hr) | Tekuća formulacija za inhalaciju koja sadrži rpl554 | |
| JP2018030871A (ja) | 非刺激性の眼科用ポビドンヨード組成物 | |
| JP2022550664A5 (enExample) | ||
| US20100197694A1 (en) | Compositions and methods for treatment of diseases and conditions with increased vascular permeability | |
| US20100202979A1 (en) | Compositions and methods for treatment of pulmonary diseases and conditions | |
| US20110244058A1 (en) | Compositions and methods for treatment of pulmonary diseases and conditions | |
| CN103347518A (zh) | 含有抗毒蕈碱药物的无推进剂液体制剂 | |
| JP2005531528A5 (enExample) | ||
| De Luca et al. | Intrapulmonary drug administration in neonatal and paediatric critical care: a comprehensive review | |
| JP6038867B2 (ja) | テトラチオモリブデン酸の治療的使用 | |
| KR100706725B1 (ko) | 디아미노트리플루오로메틸피리딘의 유도체를 함유하는 폐부전 치료제 또는 예방제 | |
| WO2025162212A1 (zh) | 一种药物组合物、器官保存液及其应用 | |
| KR102391494B1 (ko) | 몬테루카스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 안정성이 개선된 액상 제제 및 이의 제조방법 | |
| TWI422368B (zh) | 治療慢性阻塞性肺疾之組成物 | |
| JP2017530988A5 (enExample) | ||
| JP2017500345A (ja) | モンテルカストまたはその医薬的に許容しうる塩を含む液体製剤およびその製造方法 | |
| RU2021109697A (ru) | Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции | |
| MXPA06004687A (es) | Uso de bh4 para el tratamiento de enfermedades respiratorias. | |
| NZ767295B2 (en) | Liquid Inhalation Formulation Comprising RPL554 | |
| NZ729796B2 (en) | Liquid inhalation formulation comprising rpl554 | |
| RU2022103508A (ru) | Фармацевтическая композиция, содержащая энсифентрин | |
| NZ767296B2 (en) | Liquid Inhalation Formulation Comprising RPL554 |